Zobrazeno 1 - 10
of 267
pro vyhledávání: '"J. Stjernschantz"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J Stjernschantz, A Alm
Publikováno v:
Current Opinion in Ophthalmology. 7:11-17
Latanoprost is a new prostaglandin F2 alpha analogue specifically developed for the treatment of glaucoma. Latanoprost is a selective FP receptor agonist, with a primary mode of action of increased uveoscleral outflow of aqueous humor. A dose of 50 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4e9890c90c1b2a26f65b4136e2b596b
https://doi.org/10.1097/00055735-199604000-00003
https://doi.org/10.1097/00055735-199604000-00003
Latanoprost, the active principle of Xalatan(R) eye drops, is a prostaglandin F-2 alpha analogue in widespread use for the treatment of glaucoma. During chronic treatment with the drug, an increased pigmentation of the iris was observed in both prima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3730::5967259909b84db0a954b89194862192
http://hdl.handle.net/11588/154366
http://hdl.handle.net/11588/154366
Autor:
J, Stjernschantz
Publikováno v:
Investigative ophthalmologyvisual science. 42(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d195c51f1b33a6aa4b4353aca18d30ec
https://pubmed.ncbi.nlm.nih.gov/11328717
https://pubmed.ncbi.nlm.nih.gov/11328717
Publikováno v:
Pigment cell research. 13(3)
Latanoprost, the active principle of Xalatan eye drops, is a prostaglandin F2alpha analogue in widespread use for the treatment of glaucoma. During chronic treatment with the drug, an increased pigmentation of the iris was observed in both primates a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0bb59c8f655184ec73e23c1e55985c35
https://pubmed.ncbi.nlm.nih.gov/10885672
https://pubmed.ncbi.nlm.nih.gov/10885672
Publikováno v:
Arzneimittel-Forschung. 49(3)
Latanoprost (13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF2a isopropyl ester, CAS 130209-82-4 PhXA41, Xalatan) is an antiglaucoma prodrug which enhances the bioavailability of the drug into the eye compared to the corresponding acid. The pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e6039e215ad88443669a5ca2ba9d008
https://pubmed.ncbi.nlm.nih.gov/10219467
https://pubmed.ncbi.nlm.nih.gov/10219467
Publikováno v:
Arzneimittel-Forschung. 49(3)
Latanoprost (13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF2 alpha-isopropyl ester, CAS 130209-82-4, PhXA41, Xalatan), an antiglaucoma drug, labelled with tritium at carbon 13 and 14 (4.8 micrograms, 20.8 MBq/eye) was administered topically on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2d62f76162470bd5783e39c1f70cd86a
https://pubmed.ncbi.nlm.nih.gov/10219468
https://pubmed.ncbi.nlm.nih.gov/10219468
Publikováno v:
Arzneimittel-Forschung. 49(3)
Latanoprost (13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF2a- isopropyl ester, CAS 130209-82-4 PhXA41, Xalatan) is a prodrug used for reduction of the intraocular pressure in the treatment of glaucoma. The pahrmacokinetics of this drug was studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d2a295f350b97f1a23d201fb11c79dc1
https://pubmed.ncbi.nlm.nih.gov/10219466
https://pubmed.ncbi.nlm.nih.gov/10219466
Autor:
C B, Camras, M B, Wax, R, Ritch, R, Weinreb, A L, Robin, E J, Higginbotham, J, Lustgarten, W C, Stewart, M, Sherwood, T, Krupin, J, Wilensky, G A, Cioffi, L J, Katz, R A, Schumer, P L, Kaufman, D, Minckler, T, Zimmerman, J, Stjernschantz
Publikováno v:
American journal of ophthalmology. 126(3)
To determine the efficacy and safety of latanoprost treatment for 1 year in glaucoma patients, and to evaluate the effects of switching from timolol to latanoprost therapy.Latanoprost 0.005% was topically applied once daily without masking for 6 mont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::55dcec5dccd81cd1e55b3f523d4ba486
https://pubmed.ncbi.nlm.nih.gov/9744372
https://pubmed.ncbi.nlm.nih.gov/9744372
Publikováno v:
Ophthalmology. 103(11)
To determine efficacy and safety of latanoprost, a prostaglandin analog for glaucoma, during 1 year of treatment.After baseline measurements, 0.005% latanoprost was topically applied once daily for 12 months in patients from Scandinavia, the United K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4a351cc734d4ff91aeda8422b5e01446
https://pubmed.ncbi.nlm.nih.gov/8942890
https://pubmed.ncbi.nlm.nih.gov/8942890